|
AstraZeneca licenses rights to Synairgen asthma drug
Yahoo News LONDON (Reuters) – AstraZeneca has struck a deal worth up to $232 million in milestone payments to license in rights to a drug from Synairgen for viral-induced exacerbation in asthma. Britain's second biggest drugmaker – subject of a takeover bid by … |
View full post on asthma – Google News